EC strips drug safety measures from patient info proposal to meet 2012 deadline
This article was originally published in Scrip
The European Commission has backtracked on plans to incorporate some new drug safety measures into the draft legislation on information to patients, in an effort to make sure that the measures are approved in time for the implementation of the new pharmacovigilance rules in mid-2012.
You may also be interested in...
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.